Abstract | BACKGROUND: OBJECTIVE: SUBJECTS: METHODS: This was a 32-week, randomized, open-label, two-period, cross-over comparison between bedtime glargine and twice-daily detemir insulin, involving pre-pubertal children in care at a diabetes pediatric centre. After a 8-week-run-in period subjects were randomized to bedtime glargine or twice-daily detemir insulin administration. After a 12-week period treatments were inverted and continued for additional 12 weeks. RESULTS: Overall, 15 pre-pubertal children (53.3% males, mean age 8.6±1.5 years, duration of diabetes 4.2±1.5 years) completed the study. Groups did not differ for GH/IGF axis and HbA1c levels. Treatment with glargine was associated with lower fasting glucose values than treatment with detemir (8.1±1.5 vs. 8.2±1.7 mmol/L, p=0.01). Incidence rate of hypoglycemia was not different between insulin treatments ( IRR=1.18, 95%CI 1.00-1.38; p=0.07). Detemir treatment was associated with a higher increase in body weight (p=0.008) and height (p=0.02) when compared with glargine. CONCLUSION: Detemir and glargine not show significant differential effects on the GH/IGFI axis. The greater weight gain and height associated with detemir treatment, apparently not related to the level of pubertal growth, deserve further investigation.
|
Authors | V Cherubini, B Pintaudi, A Iannilli, M Pambianchi, L Ferrito, A Nicolucci |
Journal | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
(Exp Clin Endocrinol Diabetes)
Vol. 124
Issue 5
Pg. 276-82
(May 2016)
ISSN: 1439-3646 [Electronic] Germany |
PMID | 27023008
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © Georg Thieme Verlag KG Stuttgart · New York. |
Chemical References |
- Hypoglycemic Agents
- IGF1 protein, human
- Human Growth Hormone
- Insulin Glargine
- Insulin Detemir
- Insulin-Like Growth Factor I
|
Topics |
- Child
- Cross-Over Studies
- Diabetes Mellitus, Type 1
(drug therapy)
- Female
- Human Growth Hormone
(metabolism)
- Humans
- Hypoglycemic Agents
(administration & dosage, pharmacology)
- Insulin Detemir
(administration & dosage, pharmacology)
- Insulin Glargine
(administration & dosage, pharmacology)
- Insulin-Like Growth Factor I
(metabolism)
- Male
- Treatment Outcome
|